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Hypoglycaemia s a major complication of severe malaria [(1990) Trans. Roy. Sot. Trop. Med. 84 (suppl. 2) l-651, especially cerebral malaria, in 
which it is associated with increased mortality [(1990) Lancet 336. 1039-1043; (1989) Quart. J. Med. (New series) 71, 441-4591; however, the 
mechanisms responsible have not been fully explained. Preparations containing toxic malaria ntigens (TMA) released by blood stage Pkwrmdiunr 
podii malaria parasites have been shown to induce hypoglycaemia in mice lasting at least 8 h [(1992) Clin. Exp. Immunol. (in press)]. Here we report 
that TMAs can act synergistically with insulin in both stimulating lipogenesis and inhibiting lipolysis in rat adipocytes in vitro, and, furthermore. 
that they act synergistically with insulin in the induction of hypoglycaemia in vivo. 
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I. INTRODUCTION 
Hypoglycaemia is a major complication of falcipa- 
rum malaria, particularly in children and pregnant 
women [I], and is associated with increased mortality in 
patients with cerebral malaria [2,3], it is also a risk 
factor for residual neurological sequelac in treated pa- 
tients is]. Several suggestions have been put forward as 
to the possible cause of hypoglycaemia n malaria, in- 
cluding increased glucose consumption by both host 
and parasite, reduced levels of liver glycogen, impaired 
hepatic gluconeogenrsis, and the production of cytoki- 
nes, such as tumor necrosis factor (TNF), interleukin-1, 
lymphotoxin, and interleukin-6 [1,6]. We have recently 
shown that toxic malaria antigens (TMA) released by 
blood stage Plustt~odiut~z yoelii induce hypoglycaemia n
mice [4], Similar, if not identical, antigens have previ- 
ously been extensi*:ely characterized by means of their 
TNF-inducing capabilities both in vivo in mice and in 
vitro on macrophages [7,8], however, a monoclonal an- 
tibody which neutralizes the cytotoxicity of TNF did 
not prevent the induction of hypoglycaemia [4]. These 
results uggested to us that the hypoglycaemio might be 
due to the antigens acting other than through the induc- 
tion of TNF. We therefore looked for a direct effect of 
the antigens on metabolism by measuring their ability 
to induce lipogenesis or inhibit lipolysis in rat adi- 
pocytes in vitro. In this paper we show that TMAs can 
synergistically enhance insulin effects both on lipogene- 
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sis and lipolysis. In addition, a synergistic effect between 
insulin and TMAs in vivo has been demonstrated. 
2. MATERIALS AND METHODS 
2. I, Toxic rduriu uuligem 
TMAs were prepared as described previously [4] using the YM 
lethal variant of P/usrtrorlirmr yuclii. Washed, parrsitised crythrocytes 
with more than 50% parasitacmia were incubated in RPM1 culture 
medium (Gibco. pH 7.3) at IO” parasitised cells per ml overnight on 
a roller at 37°C. Next day, supernatants were collected after ccntrifu- 
gation at 500 xg for IO min, boiled for 5 min and centrifuged at 1,300 
x I. A Plusr?rorlilajrlirlc@anrrrr supernatant was kindly provided by Dr. 
H.G. Hcidrich (Max-Plank Institute, Germany). Spent culture me- 
dium from strum-free mcrozite harvest was lyophilized and reconsd. 
tutcd in stcrilc phosphate-buffered saline (pH 7.3). 
2.2. Prottusc digwiorr 
In addition 3 of the 7 Plu.wmhrn prlii supernatants were incu- 
bated for 24 h at 37°C with 10 mg/ml of pronasc E (Sigma), boiled 
for 5 min, dialyscd against pltosphatc~buffered saline (pH 7.3) and 
mixed with polymyxin B-agarose (5 mdml) and then centrifuged to 
remove any bacterial cndotoxin. 
Adipocytes were obtained from epididymal adipose tissues of 6- 
week-old nlale Sprague-Dawley rats by digestion with collagenuse [9]. 
The cells were then incubated for I h at 37OC (gas phase = OJC02. 
955) in 4 ml vols. of Krcbs-Henseleit bicarbonate mdium con’zining 
bovine albumin (10 mg/ml). 5 mM [U-“CJghtcose (approx. lOO,ooO 
dpmlmmol) and the indicated concentrations of bovine insulin with 
or without 100 ~1 aliquots of TMA preparations. Incubations were 
terminated by the addition of propan-2sl/hcxane/O/0.5 m H2S0, 
(40: lO:l), followed by extraction of lipids into hexanc [IO], and quan- 
titation by scintillation counting. All values are cxprcsseci relative to 
the basal condition without insulin or TMAs. 
Adipocytes were incubated for I h in 4 ml vois. of Kwbs-Hennh!it 
bicarbonate medium containing 5 mM glucose, 1 PM noradrenaline. 
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bovine albumin (40 mg/ml) and purified calf intestine adenosine deam- 
inase (ADase) as indicated. Incubations were terminated by addition 
of perchlorie acid followed by neutralization of acid-soluble xtracts 
[11], which were then assayed for glycerol by an enzymic method [12]. 
2.5. hlduc¢ion of hyt~oglycaemia in vh,o 
Female outbred Tuck mice (7 weeks of age) were injected itttra- 
peritoneally with eitl~er 0.025 U of insulin, 0.5 ml of TMA or a 
combination of insulin + TMA. Two separate preparations ofantigen 
were used. Blood glucose was determined from a drop of tail blood 
using t31ucostix and Ames Glucometer (Miles Ltd.). 
3. RESULTS 
3.1. Lipogenesis 
The ability oFTMAs to mimic some of the actions of 
insulin in vitro was investigated using adipocytes, ince 
glucose metabolism and lipolysis are highly sensitive to 
insulin in these cells. A dose-dependent stimulation of 
lipogenesis was seen in only three of seven antigen prep- 
arations alone, but remarkably, all seven of them acted 
synergistically with insulin. At maximally effective con- 
centrations, insulin alone increased lipogenesis by 1.5- 
2-fold, yet, when combined with the antigens, the re- 
sponse to higher concentrations of insulin was doubled 
(Fig. 1). The antigens did not appreciably alter the ECsa 
for insulin, however, which was approximately 10 "~° M. 
In three other experiments (results not shown) the anti- 
gens actually decreased lipogenesis by 16% yet still 
acted in syncrgy with insulin to increase the response to 
3 x 10 -9 M insulin by 40%. A preparation from the 
human malaria parasite, Plasmodium falciparum, also 
acted synergistically with insulin to increase lipogenesis 
by 33% (mean of  2 experiments). Pronase treatment of 
the Plasmodium yoelii antigens did not affect their abil- 
ity to act in synergy with insulin in vitro or induce 
hypoglycaemia in vivo [4]. Neither control preparations 
from uninfected crythrocytes (n = 5) nor bacterial 
lipopolysaccharide (even at 100 pg/ml) (n = 3 ), a well- 
known inducer of TNF and hypoglycaemia, showed 
any synergy with insulin (data not shown). 
3.2. Lipolysis 
Insulin also inhibits lipolysis in adipocytes when this 
process has been stimulated by various receptor ag- 
onists, e.g. noradrenaline (see Fig. 2 where ECs0 for 
insulin -- approz. 10 -~° M). Without modification of the 
experimental design, no synergy between the TMAs and 
high concentrations of insulin was detected in this sys- 
tem; this is because lipolysis is almost completely sup- 
pressed by the concentrations of insulin at which syn- 
ergy was seen in the lipogenesis experiments. Suppres- 
sion can be overcome, however, by the addition of low 
concentrations of adenosine deaminase (ADas¢). This 
enzyme removes adenosine [13,14] (which is en- 
dogenous to the adipocyte incubation system [15]), in- 
creases responsiveness to insulin [14,16], and causes 
tonic inhibition of iipolysis through O~ [17,18]. TMA 
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Fig. 1. Toxic malaria antigens (TMA) act synergistically with insulin 
to increase [~C]glucose incorporation into adipocyte lipids. (A) o, 
without TMA; o, with TMA. The values are means of 2 experiments 
using 2 separate cell preparations and 2 separate antigen preparations. 
(B) A, with TMA alone; l, with insulin (3 × l0 -~ M); A + !, with TMA 
and insulin, n = 7 using 7 separate cell preparations and 7 different 
antigen preparations. Student's t.test indicated P < 0.05 for A vs. 
basal; P < 0.0005 for I vs. basal; P < 0.005 for A + I vs. i. The bars 
indicate S.E.M. 
preparations alone did not affect noradrenalinc-stimu- 
lated lipolysis (results not shown), but when the maxi- 
mal inhibition of lipolysis by insulin was attenuated by 
ADasc at 1 mU/ml, they induced a small, but signifi- 
cant, enhancement of insulin action (Fig. 2). When 
ADase was present at 3 mU/ml, the effect of insulin 
alone was even less (-7%), but it was significantly am- 
plified to -25% by the antigens. At 1,000 mU/ml of 
ADase insulin did not inhibit noradrenaline-stimulated 
lipolysis (Fig. 2) and no effect of the antigens was ob- 
served (results not shown). 
3.3. Effects on blood ghtcoze in rive 
TMA preparations and insulin also acted synergisti- 
cally to lower the blood glucose concentration of mice, 
aa is most clearly demonstrat~l by the experiment sum- 
marized in Fig. 3. As previously shown [4] TMAs alone 
induced hypoglycaemia more slowly than insulin. 
Whereas injection of insulin of 0.025 U/mouse caused 
little change in blood glucose, the combinati, on of TMA 
+ insulin acted synergistically to produce a significantly 
lower blood glucose concentration at 0.5, 1 and 4 h, 
compared to either TMAs or insulin alone (Student's 
t-test, P < 0.01 in all cases). 
4, DISCUSSION 
The novel finding from this study is that insulin and 
toxic malaria antigen (TMA)  preparations can act syn- 
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Fig. 2. Toxic malaria ntigens (TMA) increase the antilipolytic effect 
of insulin when low concentrations of adenosine deaminase are pres- 
ent. (A) Insulin-dose-response curves were obtained in the absence of 
ADase (o); with 1 mU/ml ADase (m); with 3 mU/ml ADase (o), and 
with 1,000 mU/ml ADase (~), n = 2 using 2 separate adipoeyte prep- 
arations, (B) This demonstrates the percentage inhibition of noradre- 
naline-stimulated lipolysis achieved by 10 -N M insulin at different 
concentrations of ADase in the absence (open bars) or the presence 
(filled bars) of 100 ml aliquots of TMA. n = 4 using 2 separate cell 
preparations and 4 separate TMA preparations. *P < 0.05 and **P 
< 0,00l for the enhancement ofinsulin action by the antigen prepara. 
tions (Student's t-test). The bars indicate S.E.M. 
ergistically in vivo and in vitro. Although adipocytes 
were chosen here as a convenient test system, other 
tissues must be involved in this synergistic interplay 
between insulin and the antigens in vivo. The amplitude 
and rapidity of the synergistic effects on blood glucose 
seen in Fig. 3 are unlikely to be due solely to effects on 
adipose tissue, and it seems probable that similar syn- 
ergy occurs in skeletal muscle and/or liver. 
The TMAs appear to be phospholipids [4], and the 
induction of hypoglycaemia in vivo can be competi- 
tively inhibited by inositol monophosphate or blocked 
by antiserum against inositol monophosphate, suggest- 
ing that the active component contains an inositol phos- 
phate motif [4]. This structure isalso present in inositol 
phosphate oligosaccharidc(s) from mammalian plasma 
membranes, which mimic insulin action without being 
synergistic with the hormone [19]. Insulin-like stimula- 
tion of glucose metabolism and inhibition of lipolysis 
have also been reported for a haemodialysate [20] and 
for a fragment from a Trypanosoma brucei glyco- 
sylphosphatidylinositol (GPI)-anchored protein [21]. 
Whilst various other preparations containing an inosi- 
tol phosphate motif have been shown to have substan- 
tial insulin-like ffects [22-25], including inhibition of 
!ipolysis [21,26,27]. TMAs appear to be novel in their 
ability to act in synergy with insulin. In contrast to GPI 
anchors of parasite antigens which are disrupted by 
treatment with nitrous acid [28], the ability of TMAs to 
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Fig. 3. Synergistic effect of toxic malaria ntigens (TMA) and insulin 
on blood glucose concentrations in mice. The values are 
means _+ S.E.M. of mice injected with 0.025 U insulin (o, n = 12); 0.5 
ml TMA (z~, n = 8) or a combination of both in'.ulin and TMA 
(O, n = 8). 
cause hypoglycaemia is not affected by nitrous acid [4], 
suggesting differences in structure. As far as we are 
aware, the only parallel to our findings is the effect of 
a MHC Class I antigen-derived peptide, ,t~h_ieh nhances 
insulin-stimulated glucose uptake by adipoeytes, possi- 
bly by inhibiting insulin receptor internalization [29]. 
The clinical picture of hypoglycaemia is often compli- 
cated by the hyper-insulinaemic effect of quinine che- 
motherapy [1,30], or by the recurrence of hypogly- 
caemia in the absence of hyper-insulinaemia, or by un- 
responsiveness following dextrose infusion [1,31]. We 
propose that hypoglyeaemia during malaria infection 
may result from a direct effect of parasite antigens on 
host tissues, and that the toxic antigens may also exac- 
erbate the hypoglycaemia of patients who have high 
insulin levels as a result of quinine treatment. 
Further characterization f the molecule(s) involved 
and elucidation of their mechanism of action are re- 
quired to increase our understanding of the complica- 
tions of malaria, and for the development of anti-dis- 
ease vaccines and therapy [32], and possibly also for 
defining novel substances to decrease insulin resistance 
in Type I1 diabetes and other clinical situations. 
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